TU Dresden-founded drug discovery platform operator Dynabind has advanced research from the lab of Yixin Zhang in the university’s B Cube Center for Molecular Bioengineering.

Psyomics has added an undisclosed seed sum to capital previously raised from Parkwalk Advisors-managed vehicles Opportunities Fund and University of Cambridge Enterprise Fund.

A consortium involving public-private partnership HTGF has supplied funding to University of Bremen spinout Mirdetect to help a molecular diagnostics blood draw for testicular cancer.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Cambridge Enterprise and CIC featured in cancer therapy developer PolyProx Therapeutics’ seed round, which will coommercialise research from the university’s pharmacology department.

UCL bowel cancer diagnostics spinout Odin Vision has attracted the UCL Technology Fund in a round that will support trials of its first computer vision-powered product.

Spun out of University of Nantes and research institute Inserm, GoLiver Therapeutics hopes to catalyse a stem cell-based regenerative drug candidate for the treatment of acute and chronic severe liver failure.

Founded on inventions from Centre for Quantum Technologies, Speqtral is now set to commercialise its first application for quantum communications satellites.

Amgen is among the seed investors for Stanford-licensed drug release technology developer Navan Technologies, which hopes its nanoinjection technique will enable more cell and gene therapies to be produced at scale.

Sports Tech Tokyo, a joint sportstech accelerator initiative between Dentsu and Scrum Ventures, has chosen the first group of startups since its launch in October last year.